In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis
Authors:
- Alain MeyerAMAlain Meyer
- Guillaume LefevreGLGuillaume Lefevre
- Guillaume BierryGBGuillaume Bierry
- Aurélie DuvalADAurélie Duval
- Sébastien OttavianiSOSébastien Ottaviani
- Olivier MeyerOMOlivier Meyer
- Anne TournadreATAnne Tournadre
- Benoit Le GoffBGBenoit Le Goff
- Laurent MesserLMLaurent Messer
- Anne Laure BuchdahlABAnne Laure Buchdahl
- Michel De BandtMBMichel De Bandt
- Christophe DelignyCDChristophe Deligny
Open Access
- 1 May 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (20) , e523
Abstract
Anticitrullinated peptide/protein antibodies (ACPA), which are highly specific for rheumatoid arthritis (RA), may be found in some patients with other systemic autoimmune diseases. The clinical significance of ACPA in patients with antisynthetase syndrome (ASS), a systemic disease characterized by the association of myositis, interstitial lung disease, polyarthralgia, and/or polyarthritis, has not yet been evaluated with regard to phenotype, prognosis, and response to treatment. ACPA-positive ASS patients were first identified among a French multicenter registry of patients with ASS. Additionally, all French rheumatology and internal medicine practitioners registered on the Club Rhumatismes et Inflammation web site were asked to report their observations of ASS patients with ACPA. The 17 collected patients were retrospectively studied using a standardized questionnaire and compared with 34 unselected ACPA-negative ASS patients in a case–control study. All ACPA-positive ASS patients suffered from arthritis versus 41% in the control group (P < 0.0001). The number of swollen joints was significantly higher (7.0 ± 5.0 vs 2.9 ± 3.9, P < 0.005), with a distribution resembling that of RA. Radiographic damages were also more frequent in ACPA-positive ASS patients (87% vs 11%, P < 0.0001). Aside from a significantly higher transfer factor for carbon monoxide in ACPA–ASS patients, lung, muscle, and skin involvements had similar incidences, patterns, and severity in both groups. Although Nonbiologic treatments were similarly used in both groups, ACPA-positive patients received biologics more frequently (59% vs 12%, P < 0.0008), mostly due to refractory arthritis (n = 9). Eight patients received anti-Cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) with good efficacy and tolerance, whereas 2 of the 5 patients treated with antitumor necrosis factor drugs had worsened myositis and/or interstitial lung disease. After a >7-year mean follow-up, extra-articular outcomes and survival were not different. ACPA-positive ASS patients showed an overlapping RA–ASS syndrome, were at high risk of refractory erosive arthritis, and might experience ASS flare when treated with antitumor necrosis factor drugs. In contrast, other biologics such as anti-CD20 mAb were effective in this context, without worsening systemic involvements.Keywords
This publication has 43 references indexed in Scilit:
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanerceptClinical Rheumatology, 2011
- Antisynthetase Syndrome Presenting as Rheumatoid-Like PolyarthritisJCR: Journal of Clinical Rheumatology, 2010
- Anticyclic Citrullinated Peptide Antibodies as Markers of Erosive Arthritis in Antisynthetase Syndrome: Table 1.The Journal of Rheumatology, 2010
- Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosisRheumatology, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung diseaseEuropean Respiratory Journal, 2009
- Citrulline Dependence of Anti-Cyclic Citrullinated Peptide Antibodies in Systemic Lupus Erythematosus as a Marker of Deforming/Erosive ArthritisThe Journal of Rheumatology, 2009
- Anti–citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritisArthritis Care & Research, 2009
- Development of antisynthetase syndrome in a patient with rheumatoid arthritisRheumatology International, 2009